Last updated on November 2017

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis


Brief description of study

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis

Detailed Study Description

To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in subjects with moderately to severely active UC who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2.

Clinical Study Identifier: TX15254

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

West Michigan Clinical Research Center

West Michigan Clinical Research Center
Wyoming, MI USA
  Connect »